Description

RETATRUTIDE (20MG) – BENEFITS MAY INCLUDE

Superior Weight Loss: Phase 3 trials (Eli Lilly) show up to approximately 24.2% mean body weight reduction at 48 weeks (12mg dose), greater than GLP-1 or dual agonists.

Improved Glycemic Control: Significantly lowers A1C by up to approximately 2.2% from baseline in Phase 3 trials.

Lipid Panel Improvements: Reduces total cholesterol, LDL-C, triglycerides, and non-HDL-C while increasing HDL-C, supporting cardiovascular health.

Fatty Liver (NAFLD): Phase 2 data shows up to approximately 80% relative reduction in liver fat content (MRI-PDFF), indicating strong potential to reverse fatty liver.

Cardiovascular Benefits: Improves key risk factors including blood pressure, waist circumference, and inflammatory markers.

Cancer Benefits: Preclinical studies suggest potential anti-tumor effects, including reduced tumor growth, angiogenesis, and enhanced immune response.

Eli Lilly Phase 3 Trials: Ongoing SURMOUNT-5 (obesity), SURPASS-CVOT (cardiovascular outcomes), and additional safety and efficacy studies.

Well-Tolerated: Phase 2 and 3 trials report a safety profile consistent with incretin-based therapies, with most side effects being mild to moderate.